Announcements Trials
Browse Landscape

Phase

Phase 2 56Phase 3 24Phase 1 21Phase 1/2 13Phase 2/3 4Phase NA 3Phase EARLY_PHASE1 1Phase 4 1

Status

Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Gastrointestinal 1

Conditions

Breast Neoplasms 3Stomach Neoplasms 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Ado-Trastuzumab Emtansine × Clear all
NCT05288777 2025-04-18

Breast53

University of Virginia

Phase 2/3 Recruiting
45 enrolled
Breast

Breast Neoplasms

NCT04924699 2023-03-17

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Shanghai Miracogen Inc.

Phase 2/3 Unknown
350 enrolled
Breast

Breast Neoplasms

NCT02568839 2020-08-13

PREDIX HER2

Karolinska University Hospital

Phase 2/3 Active not recruiting
202 enrolled
Breast

Breast Neoplasms

NCT01641939 2017-05-12

A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Hoffmann-La Roche

Phase 2/3 Terminated
415 enrolled 25 charts
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡